

## Applied Pharmacoeconomic and Outcomes Research Forum

February 3<sup>rd</sup> 2012



## Eight Forums and Five Years ...

- 1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
- 2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
- 3. Quality Adjusted Life Years (QALY's) for Decision Making: Views from Canada & the US
- 4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
- Real World Data for Decision Making: Moving Beyond Clinical Trials
- 6. Pharmacoeconomics of Pharmacogenomics
- 7. Pharmacoeconomics & Pricing: Now & After Health Care Reform
- 8. What is the Business Case for Quality Improvement Initiatives?





Charles Daniels, R.Ph., Ph.D. UCSD Healthcare Department of Pharmacy

Ted Ganiats, MD
UCSD School of Medicine

Mirta Millares, Pharm.D., FCSHP, FASHP Kaiser Permanente – CA Regions Darlene Fujimoto, Pharm.D UCSD Healthcare Department of Pharmacy

Jan D. Hirsch, R.Ph., Ph.D.
UCSD, Skaggs School of Pharmacy
& Pharmaceutical Sciences

Anthony P. Morreale, Pharm.D., MBA, BCPS PBM Services, Department of Veterans Affairs

Robert Schoenhaus, Pharm.D.
Sharp HealthCare



## Sponsors - Thanks!






biogen idec



GOAL: Sustainable fund for future PE Forums







## Agenda

How are quality improvement guidelines, such as HEDIS measures, really developed?

Health plan perspective of complying with quality improvement guidelines; benefits, costs, and value.

Do HEDIS measures reflect good value from societal and health plan perspective?

Panel Q & A/Discussion

**Future Forums – Discussion** 

Ted Ganiats, MD

Professor, Department Family and Preventive Medicine, UCSD

Catherine MacLean, MD, PhD

Staff Vice President, Quality Improvement, Center for Quality Measures & Improvement, WellPoint

Michael S. Broder, MD, MSHS

President, Partnership for Health Analytic Research

ALL

ALL



